Hunan Warrant Pharmaceutical (SHA:688799) is planning to invest up to 500 million yuan in the phase two expansion of its high-end active pharmaceutical ingredient (API) and intermediate green manufacturing base in Changsha in China's Hunan Province.
The expansion is expected to scale up API production, strengthen the company's green manufacturing edge and drive long-term growth, according to a Monday filing with the Shanghai bourse.
Annual output will be 3,000 tons of high-end APIs and intermediates.
Construction is expected to take between one and three years.
Shares of the company were down 1% Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.